Merck Points To Antibody-Drug Conjugate Potential During Another Growth Quarter

 
• By Joseph Haas
  
Merck
Merck reported another strong quarter for Keytruda thanks to earlier-stage treatment
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business